PharmaCyte Biotech, Inc. (PMCB): Investment Report

Overview

PharmaCyte Biotech, Inc. (PMCB) is a biotechnology company that is developing and commercializing cellular therapies for cancer treatment. With its proprietary Cell-in-a-Box technology, PMCB has the potential to revolutionize the cancer treatment landscape. As the company continues to advance its pipeline and technology, we believe that PMCB is an attractive investment opportunity for those looking to capitalize on the growing demand for innovative cancer treatments.

Core Metrics

• Current price: $1.93 USD
• 52-week high: $2.58
• 52-week low: $1.39
• Market Cap: $14.88 million
• P/E Ratio: N/A
• Earnings per Share: -$1.80
• 50-day average: $1.85
• 200-day average: $2.09
• Analyst Recommendations: Hold (1 analyst)

Financial Performance

PharmaCyte Biotech's financial performance has been mixed, with the company reporting a loss in earnings per share (EPS) of -$1.80. The company has a total cash of $32.64 million and a free cash flow of $3.13 million. However, its operating cash flow is -$2.87 million, indicating that the company is still in the early stages of development. Despite this, we believe that PMCB's proprietary technology and pipeline have the potential to drive future growth.

Growth Prospects

PharmaCyte Biotech's growth prospects are promising, with the company's Cell-in-a-Box technology having the potential to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company has a cooperation agreement with Iroquois Master Fund Ltd. and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd., which could provide additional revenue streams. We believe that PMCB's technology and pipeline could drive future growth and make it an attractive investment opportunity.

News and Updates

Recent news articles have highlighted the potential of genetically engineered "golden lettuce" to bring 30x more nutrients to consumers. While this news is not directly related to PMCB, it highlights the growing trend towards innovative and healthy food options, which could drive demand for PMCB's technology. Additionally, PMCB has been featured in news articles regarding its stock quotes, forecast, and news summary, indicating growing interest in the company.

Upgrades and Downgrades

In November 2021, HC Wainwright & Co. initiated coverage on PMCB with a Neutral rating, indicating that the company's potential is being recognized by analysts.

Summary

In summary, PharmaCyte Biotech, Inc. (PMCB) is a biotechnology company with a proprietary Cell-in-a-Box technology that has the potential to revolutionize the cancer treatment landscape. While the company's financial performance has been mixed, we believe that its technology and pipeline have the potential to drive future growth. With a growing trend towards innovative and healthy food options, PMCB could be an attractive investment opportunity for those looking to capitalize on the demand for cellular therapies for cancer treatment.

Disclosures

The information on this website should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on other content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Under no circumstances should any information provided on this website or social media platforms be construed as an offer soliciting the purchase or sale of any security, nor should it be construed as an offer to provide investment advisory services.